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Sex differences in incidence and prevalence of and morbidity and mortality from cardiovascular disease
are well documented. However, many studies examining the genetic basis for cardiovascular disease fail
to consider sex as a variable in the study design, in part, because there is an inherent difﬁculty in
studying the contribution of the sex chromosomes in women due to X chromosome inactivation. This
paper will provide general background on the X and Y chromosomes (including gene content, the
pseudoautosomal regions, and X chromosome inactivation), discuss how sex chromosomes have been
ignored in Genome-wide Association Studies (GWAS) of cardiovascular diseases, and discuss genetics
inﬂuencing development of cardiovascular risk factors and atherosclerosis with particular attention to
carotid intima-medial thickness, and coronary arterial calciﬁcation based on sex-speciﬁc studies. In
addition, a brief discussion of how ethnicity and hormonal status act as confounding variables in sex-
based analysis will be considered along with methods for statistical analysis to account for sex in car-
diovascular disease.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sex differences in incidence, prevalence, morbidity and mor-
tality from cardiovascular diseases are well documented and
represent important health disparities [1e3]. These sex differences
can be classiﬁed as those that are sex-speciﬁc such as erectile
dysfunction in men and hypertensive pregnancy disorders in
women, or conditions common to both sexes but which show sex
differences in presentation and outcomes such as hypertension,
atherosclerosis, angina, and stroke.
Sex differences in cardiovascular diseases result from a complex
interaction among genetic, hormonal and environmental factors
that provide a proﬁle of individual risk and phenotypic presenta-
tion of disease. Therefore, there is an increased interest in identi-
fying the genetic components of disease to optimize treatments
and outcomes. However, investigations into the genetics of car-
diovascular diseases in men and women are hampered by the
failure to include the sex chromosomes in genome-wide associa-
tion studies (GWAS), to account for sex as a variable in targeted
genetic analyses, and to examine hormone-gene interactions. InMedical Science 4-20, Mayo
iller).
Ireland Ltd. This is an open accessthis paper, we will provide general background on the X and Y
chromosomes, discuss how they have been ignored in GWAS of
cardiovascular disease, and discuss genetic factors contributing to
sex differences in conventional cardiovascular risk factors and
atherosclerosis with examples of sex-speciﬁc studies of carotid
intima-medial thickness, and coronary arterial calciﬁcation. Con-
founding factors of ethnicity and hormonal status also will be
considered along with some proposed methods for statistical
analysis for future studies.2. Background: the genetics of sex
In humans, sex is determined via the X and Y chromosomes.
Each somatic cell of the human body contains 23 pairs of chro-
mosomes, 22 of which are the same in both sexes (autosomes);
however females have two copies of the X chromosome, whereas
males have one copy of the X and one copy of the Y [4]. Therefore,
differences between the sexes result from the particular combina-
tion of sex chromosomes an individual possesses, as well as,
differing levels of the sex hormones. Often early studies of sex
differences compared persons with XX and XY genotypes to those
with sex chromosome monosomy (e.g. XO karyotype in Turner
syndrome) or trisomy (e.g. XXY karyotype in Klinefelter syndrome)
to distinguish whether observed sex differences were due to sexarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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[5].
As genotyping technologies have rapidly improved, studies of
the genetic basis of sex differences are no longer limited to inves-
tigating global differences in sex chromosome dosage effects, but
can directly examine the individual genes and genetic variants on
the X and Y chromosomes. In humans, the larger X chromosome
contains 813 protein coding genes, whereas the much smaller Y
chromosome contains 143 protein-coding genes, although many of
the Y genes are multi-copy genes or present in both males and fe-
males (Ensemble Genome Browser, http://www.ensembl.org); only
46 genes are on the male-speciﬁc region of the Y (MSY). The sex
chromosomes evolved from ancestral autosomes [6,7], and over the
course of evolution, the X has retained many of the ancestral genes
(98% retained), but the Y lost many (3% retained) [8]. Only 14
ancestral XeY gene pairs are still present in humans, and many of
these have important regulatory functions in regards to transcrip-
tion, translation, and protein stability [8,9]. Some of the genes in the
ancestral gene pairs retain the same function across the X and Y, but
others have diverged. Additionally, both the X and Y have acquired
new genes through evolution, with an emphasis on reproductive
function [10,11]. The Y chromosome contains the SRY gene, or sex-
determining region Y, which encodes the testes determining factor
[12]. Many other genes on the Y chromosome are related to male
sexual development and reproduction, including multicopy gene
families expressed exclusively in the testes [8,11]. The X chromo-
some also includes reproductive-related genes, such as the
androgen receptor [13], and genes important for brain develop-
ment, blood clotting, and visual pigmentation [14].
The X and Y chromosomes have developed unique properties as
compared to the autosomes, as illustrated schematically in Fig. 1
(this schematic diagram does not reﬂect the large difference in
genetic content between the X and Y chromosomes, such as the
large block of non-coding heterochromatin on the Y located in the
MSY region designated in the ﬁgure at * [11]). Unlike autosomal
pairs, the X and Y do not generally undergo recombination due to
evolutionary divergence. However, there are two regions on each
end of the X and Y chromosomes that are homologous, called the
pseudoautosomal regions (PAR), which behave like the autosomes
and do recombine [6] (Fig. 1A). For most genes in the PAR, both
copies are expressed across both sex chromosomes (XX for females
or XY for males). However, for other regions, that is, the genes on
the non-pseudo-autosomal regions, the aneuploidy causes unequal
patterns of expression across the sexes, which requires some form
of dosage compensation across males and females [15]. One
method is upregulation of X-linked genes [16]. In humans, one of
the female copies of the X chromosome is silenced during
embryogenesis to achieve dosage compensation during a process
called X chromosome inactivation [6] (Fig. 1B). The X-linked gene
XIST is expressed from the inactive chromosome, triggering DNA
methylation that is responsible for the chromosome-wide silencing
[17]. The inactive chromosome remains silent in somatic cells, but is
reactivated during meiosis. This inactivation is tissue and cell
speciﬁc, such that the maternally inherited allele may be expressed
in some cells, while the paternally inherited allele may be
expressed in others [18]. This process occurs randomly so that
usually each chromosome is inactivated in 50% of cells, although
preferentially (skewed) inactivation of one chromosome can occur
either globally or in speciﬁc tissues, as demonstrated in cardiac
muscle of mice [18]. Skewed X-inactivation has been observed in
samples from human arteries, suggesting that the cells in the pla-
que arose from a single or similar group of cells [19]. To further
complicate matters, approximately 15% of X-linked genes escape
inactivation in humans [20,21]. For these ‘escapee genes,’ both
copies are active in females (whereas males may have a singleactive copy if there is no homologous gene on the Y). Mechanisms
of dosage compensation, whether concerning X or Y speciﬁc genes
undergoing upregulation or X inactivation, or shared homologous
XeY gene pairs or pseudoautosomal genes, may be related to dif-
ferential gene expression across the sexes and are important con-
siderations for sex speciﬁc disease risk.
In contrast to the PAR on the X and Y chromosomes that is
present in both sexes, the non-PAR region of the Y chromosome
(MSY) encompasses the vast majority of the Y chromosome [11].
This region does not undergo recombination, and is inherited from
father to son as a single haplotype, reﬂecting the paternal lineage
only. Many of these genes are widely-expressed (at the RNA level),
exhibiting global regulatory functions in transcription, translation,
and other biological processes (non-reproductive), and hence may
be important to men's health beyond sex determination and sexual
reproduction [8].
Both X and Y chromosomes contribute to disease. Many rare
Mendelian genetic disorders are linked to the sex chromosomes.
According to the Online Mendelian Inheritance in Man (OMIM)
catalog of genetic disorders in humans, approximately 7% of cata-
loged phenotypes are X-linked [22]. XY males are at increased risk
compared to XX women for X-linked disorders, such as learning
disabilities and mental retardation caused by X-linked genes
important in brain development and function [14]. Hearing
impairment (DFNY1, MIM 400043) reported in a Chinese family
was the only documentedMendelian disorder showing Y-linkage in
humans [23]. However, subsequent analysis found that the condi-
tion was related to an insertion of chromosome 1 into the Y gene
rather than a mutation of a Y-chromosomal gene [24].
Much work to link the sex chromosomes to disease has focused
on such rare disorders caused by a single gene, and less is known
about the inﬂuence on complex traits with multiple genetic and
etiological components. In particular, variants on the X chromo-
some are understudied for complex traits, with signiﬁcantly fewer
genome-wide associations than the autosomes [22] (Fig. 2). Of the
over 2800 genome-wide signiﬁcant associations reported for over
300 traits in the NHGRI GWAS Catalog [25], only 15 published as-
sociations reside on the X despite representing approximately 5% of
the human genome, including 153 million nucleotide base pairs
and 1669 genes [26]. This representation is in stark contrast to the
similarly sized chromosome 7, which holds 120 published associ-
ations [22]. There are a number of reasons for this discrepancy,
including reduced power due to the use of sex-speciﬁc analyses or
low data quality, reﬂecting poor genotyping accuracy on current
genome-wide arrays and quality control issues. However, an
important reason is also that although the X chromosome is
routinely included in standard genotyping arrays, it is simply
excluded from analysis. Indeed, of the ﬁrst 53 studies that have
released publically available GWAS data, only 31 include the X
chromosome [22]. Since the number of copies of X chromosome
variants is confounded with sex, special analysis methods and
computational tools are required (discussed below); therefore the
sex chromosomes have historically been excluded to simplify an-
alyses, setting a critical precedent that needs revision.
Important issues regarding the genetics of sex differences are
not limited to large scale GWAS studies in humans but also are
critical concerning preclinical work involving model organisms. In
particular, basic science research utilizes experiments in model
organisms as critical tools to investigate human disease. However,
the genetics and biology of the sex chromosomes differs from
species to species regarding genes that are conserved and mecha-
nisms of dosage compensation [8,15]. Therefore the choice of the
model organism may be critical to the study of sex differences. The
mouse has become a favorite model organism for preclinical dis-
ease research because many genes are shared with humans,
Fig. 1. (A) Schematic of the X and Y chromosomes in males and females showing regions of shared or speciﬁc expression. This schematic is not drawn to scale, and does not include
the large heterochromatin block within the male-speciﬁc region of the Y on the q arm (denoted by *) which is not expressed. (B) Schematic of X chromosome inactivation in
multiple cells of the female body.
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by the work of the Mouse ENCODE Consortium [27]. Mice have
fewer conserved XeY gene pairs [8] and fewer genes that escape X
inactivation as compared to humans [21,28], which may suggest
that they may NOT be an ideal model organism to study the ge-
netics of sex differences for all conditions in humans.
3. Genetics of cardiovascular disease
3.1. General considerations
Cardiovascular diseases are complex traits with both sex-
speciﬁc (i.e. cardiovascular diseases associated with pregnancy,
erectile dysfunction) and sex-different etiology, pathophysiology,
symptom presentation, severity and progression [3,29,30]. The
concept that there are sex by trait interactions is not new [31] and
several methods are used to examine genetic components of
complex traits including GWAS, linkage analysis, association
studies, and candidateegene association studies. However, not all
studies of populations of men and women account for sex in the
analysis and if sex is considered, it is treated only as a confoundingvariable [32e35]. However, when sex and sex chromosomes are
considered, there is the potential to gain new insight into etiology
of disease, differences in mechanisms of progression and new tar-
gets for preventive and therapeutic interventions [36]. Failing to do
so, hampers medical progress toward optimizing individual
outcomes.
3.2. Cardiovascular risk factors
Major risk factors for cardiovascular disease include smoking,
high blood pressure, high glucose, central adiposity and high blood
lipids. While some psychosocial, economic and environmental
conditions as well as life-style choices (i.e. access to health care,
stress, smoking, diet, and activity) have physiological conse-
quences, it is important to determine which biological factors
(regulation of blood pressure, glucose, and lipidmetabolism) reﬂect
inherited components in order to optimize preventive and thera-
peutic strategies.
3.2.1. Hypertension
Men develop hypertension at younger ages than women, thus
Fig. 2. Plot of the number of published GWAS associations studies reported in the
NHGRI catalog by number of genes. Each dot represents a pair of autosomal chro-
mosomes. The ‘X’ and ‘Y’ chromosomes are plotted in red.
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of stroke [37e40]. Recall that sexual dimorphism is impacted by the
sex chromosomal complement independent of hormonal in-
ﬂuences. The Sry locus of the Y chromosome, in addition to being
required for the development of the testes, was found in experi-
mental animals to regulate tyrosine hydroxylase, a critical enzyme
in the synthesis of norepinephrine [41]. Greater activity of tyrosine
hydroxylase in men would pre-disposes them to hypertension
differently than women [42] and indeed, several large genetic
studies have identiﬁed loci on the Y chromosome associated with
hypertension in men (for review see [43]).
In addition to synthesis of adrenergic transmitter, genetic vari-
ants in alpha and beta adrenergic receptors affect vascular tone. In
women with non-obstructive coronary disease, genetic variants in
adrenergic receptors associate with resting hemodynamics and
increased risk for stroke, myocardial infarction and heart failure
[44e46]. Polymorphisms in the genes encoding enzymes and re-
ceptors for the renin-angiotensin system would inﬂuence devel-
opment of hypertension in both women and men but these
polymorphisms in women may predispose them to pregnancy
related hypertension [47]. Genetic polymorphisms in these re-
ceptors and enzyme systems also would affect a woman's response
to pharmacological agents that are used in the treatment of hy-
pertension, i.e. beta and alpha adrenergic antagonists, angiotensin
receptor antagonists, and angiotensin converting enzyme (ACE)
inhibitors. There are no sex-speciﬁc guidelines for treatment of
hypertension [48,49].
3.2.2. Inﬂammation
The Y chromosome also includes genes involved with macro-
phage activation affecting innate immunity [50,51]. Systemic
inﬂammation characterized by activation of macrophages and in-
creases in circulating levels of various cytokines contributes to
development of atherosclerosis [52]. Thus, in males, genetic risk for
development of other cardiovascular disease apart from hyper-
tension may be imparted simply by inheriting the Y chromosome.
Genes on the X chromosome also affect phenotypic expressionof inﬂammatory risk factors, including genes associated with
apoptosis, lipid oxidation, and generation of oxygen-derived free
radicals produced by the mitochondria. In an analysis of RNA levels
of 683 genes on the X chromosome obtained from individuals at
speciﬁed time intervals following a stroke, X related genes showed
greater and differential upregulation in females compared tomales.
In females, up-regulated genes were associated with post-
translational modiﬁcation of proteins, small molecule biochem-
istry and cellecell signaling; in men, up-regulated genes were
associated with cellular migration, cell trafﬁcking and cell death
[36]. This study provides evidence that cellular pathways involved
with manifestation of a particular cardiovascular outcome, in this
case stroke, differs between men and women.
3.2.3. Lipids
Much research and clinical preventive strategies have focused
on evaluating andmanaging serum lipids. Indeed, decreases in high
density lipoprotein (HDL) cholesterol and increases in low density
lipoprotein (LDL) cholesterol and total cholesterol are considered
hallmarks of cardiovascular risk. Sex steroids regulate serum lipids
and in women, genetic variants in genes for either estrogen re-
ceptor a or b associated with serum lipids, but the associations
varied by ethnic groups [53]. The extent to which lipid metabolism
shows a sex-difference independent of sex steroids is unclear
including mechanisms of lipid deposition in vascular lesions. Male
pattern of lipid deposition results in obstructive lesions within the
coronary arteries while in women the pattern is diffuse and man-
ifests as non-obstructive ischemic disease [54].
In a genome wide association study, genes of the metabolic
pathways for HDL, LDL and triglycerides associated with obstruc-
tive coronary artery disease [55] and with serum lipids in healthy
volunteers [56]. While the details of these reports are beyond the
scope of the present review, several key points serve as an example
relevant to studying the genetics of sex differences. In these studies,
there was large variability in the number of SNPs among the genes
studied and some of the variants were speciﬁc to either Caucasian
or minority ethnic groups. In these studies, sex was not considered
in the analysis. In a genome-wide analysis of loci affecting lipid
metabolism conducted in samples from approximately 20,000
persons from European countries, three loci showed sex-speciﬁc
effects. The strongest effects were in the gene for 3-hyroxy-3-
methylglutaryl-Coenzyme A reductase (HMGCoA) and in the gene
that encodes chondroitin sulfate proteoglycan (NCAN). The former
enzyme is the rate-limiting step in synthesis of cholesterol (greater
effect in females, P ¼ 0.001) and a target for statin therapy; the
latter enzyme is involved in cell adhesion and migration (greater
effect in males P ¼ 0.002). Both these loci associated with total
cholesterol. The gene encoding lipoprotein lipase (LPL) showed
greater association with HDL in males compared to females
(P ¼ 0.006) [57]. The age distribution among participants in that
study was broad (18e104 years). It is unclear at this time whether
these associations would remain if hormonal status was considered
in females as estrogen modulates lipid metabolism.
Two meta-analyses of genome-wide association studies evalu-
ating loci for lipid metabolism with coronary artery disease, sex-
differences, perhaps not surprisingly, were conﬁrmed in genes
regulating total cholesterol, LDL, HDL and triglycerides [58,59].
Both of these studies identiﬁed stronger associations of SNPS to
serum triglycerides in women compared to men. Because associa-
tions in one analysis were based on those that also associated with
coronary artery disease, both women and men in those studies
would most likely have phenotypic obstructive disease [59].
Statin therapy, which inhibits HMGCoA, has become a main
approach to primary prevention of coronary artery disease and
stroke. The safety and efﬁcacy of this treatment in a meta-analysis
S.J. Winham et al. / Atherosclerosis 241 (2015) 219e228 223of 27 clinical trials found the treatment of similar effectiveness in
women and men who had equivalent cardiovascular risk [60]. The
number of women included in this analysis was less than 30%. As
stated above, genetic polymorphisms in the gene for HMGCoA had
greater association lipid levels inwomen compared tomen. Genetic
polymorphisms in that gene associate with development of type 2
diabetes [61] that was shown to be increased with statin use in the
Women's Health Initiative [62]. Although there are no sex-speciﬁc
guidelines for use of statins in primary prevention strategies for
cardiovascular disease, the appropriateness related to “equivalent
risk” is recommended [63,64].
3.2.4. Metabolic syndrome
The term “metabolic syndrome” is used to deﬁne a constellation
of at least three of ﬁve risk factors for cardiovascular disease: waist
circumference (>88 cm for female and 102 cm for male), high-
density lipoprotein cholesterol (HDL-C) <50 mg/dL, triglyceride
level >150 mg/dL, fasting blood glucose >100 mg/dL, and systemic
blood pressure (systolic blood pressure 130 or diastolic blood
pressure 85 mmHg) [65]. Although two individuals with “meta-
bolic syndrome”may exhibit a different combination of three of the
ﬁve characteristics [66], the collection poses greater risk for car-
diovascular disease than any characteristic separately. Not sur-
prisingly there are sex differences in incidence and prevalence of
metabolic syndrome (independent of the target values to deﬁne the
syndrome) [67] due to sex differences in incidence of hypertension
and hyperlipidemia. Abdominal obesity shows sexual dimorphism
distinct from body mass index. In women, abdominal obesity (as
measured by waist circumference) is gaining acceptance as a
measure to be considered in assessing cardiovascular risk, but this
measure may be inﬂuenced by race/ethnicity [68,69]. Data from a
genome-wide association study of individuals of European and
European-American descent to evaluate phenotypic traits of height,
weight, body mass index, waist circumference, hip circumference
and wait-to-hip-ratio conﬁrms these assertions as only sex-
differences in loci for waist phenotypes were found [70]. Of 7 loci
associated with waist phenotype, all were found in women and not
men. Of particular interest is the variant in the gene for PPARG
encoding peroxisome proliferator-activator receptor g (PPARg), a
type II nuclear hormone receptor regulating adipocyte-
differentiation, susceptibility for obesity and insulin resistance.
PPARg binds to a site in HSD17B4, which encodes the enzyme
hydroxysteroid (17-beta) dehydrogenase involved in the conver-
sion of estrogen to estrone and beta-oxidation of fatty acids [70]. As
statins also target PPARg, and as there are documented interactions
with estrogen and endocrine disruptors in regulation of PPARg
[71e73], sex differences observed with statins and type 2 diabetes
may be related to genetic variants in PPARg [74]. Collectively, these
data identify the interaction between sex and the genetic compo-
nents of a phenotype associated with sex differences in adiposity,
and demonstrate the utility of pathway analysis to assess sex dif-
ferences in genetic components of cardiovascular risk
susceptibility.
Central adiposity is functionally linked to elevated glucose, in-
sulin resistance and type 2 diabetes. Diabetes poses about a 3 to 6
times greater risk for myocardial infarction in women compared to
men across several ethnic groups [67]. Numerous studies have
identiﬁed candidate genes involved in development of type 2 dia-
betes although discussion is beyond the scope of this review.
However, one study utilizing a meta-analysis of genetic variants on
the Metabochip identiﬁed two sex-differentiated variants in com-
bined caseecontrol populations of European and Pakistani origin:
CCND2, which encodes cyclin proteins involved with cell division,
was most signiﬁcant in males and GIPR, which encodes G-protein
coupled receptor for gastric inhibitory polypeptide that whenactivated stimulates release of insulin in response to elevated
glucose, was most signiﬁcant in females [75]. However, in the
subsequent pathway analyses, sex was not considered and the
constellation of pathways may interact in different ways in females
compared to males, given the other interactions among lipid
metabolism, glucose, metabolism and adiposity [75].
Using a metabolomics approach to investigate genetic regula-
tory networks associated with complex disease traits, 102 of 131
serummetabolites showed sex differences in expression frommore
than 3300 population based samples (Cooperative Health Study in
the region of Augsburg, KORA). A sex-speciﬁc GWAS identiﬁed a
locus of the carbamoyl-phosphate synthase 1 gene (CPS1) for
glycine, a key component in amino acid synthesis [76]. A sex-based
analysis revealed sex speciﬁc SNPs that have a greater effect on
glycine in females compared to males. CPS1 encodes a mitochon-
drial enzyme involved in hepatic nitrogen urea metabolism and
synthesis of arginine, a precursor to formation of nitric oxide, an
endothelium-derived relaxing factor the absence of which is
considered to contribute to endothelial dysfunction and progres-
sion of vascular disease. These studies underscore the ability to
analyze existing genetic data sets by sex and their potential to
provide a better understanding of mechanisms of cardiovascular
disease that may extend to understanding sex-speciﬁc risks such as
gestational diabetes and insulin resistance associated with poly-
cystic ovarian syndrome (PCOS) in women [77].
3.3. Cardiovascular anatomical pathologies
As non-invasive imaging techniques are used to evaluate the
presence and progression of asymptomatic vascular lesion char-
acteristic of cardiovascular disease, genetic components of these
complex traits warrant mention.
3.3.1. Carotid intima-medial thickness (CIMT)
CIMT is a quantitative trait showing some degree of heritability
in different ethnic populations [78]. Using candidate gene analysis,
variants associated with CIMT cluster into several gene classes:
hemostasis, extracellular matrix remodeling, endothelial function,
the renin angiotensin system, inﬂammation and antioxidation [79].
In recently menopausal women, a candidate gene analysis of genes
related to the anticoagulant, procoagulant, ﬁbrinolytic, and innate
immunity pathways, only variants in genes of the innate immunity
pathway associated with CIMT [80]. These women had endogenous
estradiol levels <40 pg/ml, and it is unknown if these associations
may change with use of menopausal hormone treatments.
Genetic contributions to carotid thickening differ along seg-
ments of artery, which may reﬂect differences in exposure to
physical forces at the carotid bifurcation [78]. Vascular stiffness in
women but not men was nominally associated with variants in
endothelial nitric oxide synthase (NOS3) gene [81]. NOS3 is
modulated by estrogen, thus, phenotypic expression of NOS3 vari-
ants should vary by hormonal status. With an average age of study
participants of 62 years, most of the women would have been
postmenopausal and estrogen deﬁcient (see section below).
A meta-analysis of GWAS studies from the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium
consisting of nine-community-based studies (age 44e76 years)
identiﬁed four genetic variants associated with CIMT: a transcrip-
tional factor (rs11781551), APOC1 (rs445925) associated with dys-
lipidemia, a telomerase inhibitor involved in chromosomal
segregation in mitosis (rs6601530) and a regulator of uric acid
(rs4712972). Contrary to these results, another GWAS study of the
Framingham community failed to identify genes associated with
increases in CIMT, in spite of large sample sizes and equal repre-
sentation of men and women [34]. Neither of these studies
Fig. 3. Ancestry informative markers (492) were used to stratify participants of the
Kronos Early Estrogen Prevention Study (KEEPS) by ethnicity using the program
STRUCTURE [80]. The STRUCTURE program uses ancestry informative markers that are
evenly distributed across the genome to identify the ancestry of each subject by using
the three HapMap 2 populations (CEU: Utah residents from the CEPH; YRI: Yoruba
from Ibudan, Nigeria; and CHB/JPT: Han Chinese from Beijing, China, and Japanese
from Tokyo, Japan) or the 1000 Genomes populations [121]. For KEEPS, CHB/JPT rep-
resents 89 HapMap Asian samples, URI represents 60 HapMap African samples and
CEU represents 60 HapMap Caucasian samples. Each circle represents an individual;
the colors represent self-identiﬁed ethnicity. E and W represent site center as from
either the east coast or west coast of the United States, respectively. Women who self-
report as USA Hispanic from the West Coast are a mixture of Native Americans and
European Ancestry, while those from the East Coast were a mixture of African and
European Ancestry.
S.J. Winham et al. / Atherosclerosis 241 (2015) 219e228224stratiﬁed analysis by sex. However, overall heritability for intima-
medial thickness of the internal carotid artery was higher for
men thanwomen, whereas heritability for intima-medial thickness
in the common carotid artery was greater for women than men
[40]. Analyses that do adjust for but do not stratify by both age and
sex preclude identiﬁcation of sex-speciﬁc genetic variance
contributing to progression of CIMT. For example, apolipoprotein
E4 (APOE4) associated with CIMT in several studies [78] but this
genemay have sex-speciﬁc considerations, since it is a more critical
risk factor for Alzheimer's disease inwomen compared tomen [82].
Several studies suggest sex-speciﬁc genetic factors contribute to
CIMT. CIMT is an independent predictor of stroke [83] and inci-
dence, prevalence and outcomes of stroke show sex disparities. One
sex-speciﬁc analysis examined the association between CIMT and
genetic variants of the phosphodiesterase 4D (PDE4D) gene, a
susceptibility gene for stroke where CIMT would provide a
phenotype for stroke risk with reduced complexity [84]. One ho-
mozygote variant had a signiﬁcant odds ratio for increased CIMT in
the overall study population. However, when these data were
analyzed by sex, the odds ratio remained signiﬁcant for men but
not women [84]. PDE4E metabolizes cyclic AMP, a key signaling
molecule involvedwith prostaglandin signaling. As this variant also
correlated with stroke in young men, it is possible that the lack of
efﬁcacy of aspirin to reduce stroke risk in men may be related to
this signaling pathway [85].
Other genetic variants showing sex speciﬁc associations with
subclinical atherosclerosis measured by CIMT include variants in
the gene for interleukin-6, an inﬂammatory cytokine, associated
with blood pressure and CIMT in Japanese women but not men
[78], for cyclin-dependent kinase inhibitor 2A (CDKN2A), a negative
regulator of cell proliferation, which showed associationwith CIMT
in men, while the genetic variation in the gene for oxidized low
density lipoprotein receptor 1 (OLR1) showed association with
CIMT only in women.
3.3.2. Coronary calciﬁcation
Prevalence of coronary calciﬁcation is greater in men than
women and varies by ethnic group [86]. Cardiovascular disease risk
factors such as hypertension, hypercholesterolemia and type 2
diabetes can exacerbate accumulation of calcium in the coronary
arteries. For example, in individuals at high risk for hypertension,
coronary calciﬁcation is associated with genes regulating collagen
formation, allograft inﬂammatory factor 1 and bone morphometric
protein receptor type 1A [35]. Other genes implicated in coronary
calciﬁcation are those for matrix metalloproteinase 9 (MMP9) [87]
matrix Gla protein (MGP) and osteopontin (OPN) [88]. How these
genetic associations might differ with hormonal status (e.g. estro-
gen) and risk for calciﬁcation in women is unknown.
In diabetics, two SNPs of the gene encoding the inﬂammatory
signaling molecule CD40 were negatively associated with coronary
calciﬁcation in a candidate gene study in European Americans [89].
However, a GWAS of African Americans did not uncover any genetic
variants signiﬁcantly associated with coronary calciﬁcation [90].
This negative ﬁnding may reﬂect failure to examine sex-speciﬁc
effects or consider that multiple genetic pathways converge to
promote calciﬁcation. Clinically relevant calciﬁcation also can exist
in persons without signiﬁcant conventional cardiovascular risk
factors. For example, in women being screened for the Kronos Early
Estrogen Prevention Study (KEEPS), about 14% were excluded
because of the presence of clinically relevant coronary calciﬁcation
(Agatston score >50) [91]. Women included in KEEPS had Agatston
score <50 with most having no calcium in their coronary arteries.
However, in those women who had Agatston score >0 but <50, a
candidate gene study associated variants in genes related to innate
immunity, elastin remodeling and post-translational modiﬁcationof proteins with coronary calciﬁcation [80]. Because these women
were estrogen deplete, it is unknown if these genetic variants
would associate with calciﬁcation following the use of menopausal
hormone therapy, as use of conjugated equine estrogen slowed
coronary calciﬁcation in women of the Women's Health Initiative
[92].
4. Confounding variables: ethnicity and hormonal status
4.1. Ethnicity
Although the genetics of ethnicity are not considered in depth in
this review, some mention is warranted given that development of
cardiovascular disease is inﬂuenced by ethnicity/race
[33,39,79,93,94]. As indicated in the preceding sections of this re-
view, some studies account for race and ethnicity with speciﬁc
designations, e.g. Caucasian of European ancestry, Mexican-
American, Han Chinese, Japanese, Dominican Republic, etc. How-
ever, studies of populations which may consist of mixed racial
origin, fail to adjust for population stratiﬁcation in genetic analyses.
For example, studies of individuals identifying as “Hispanic” are by
self-report, unrelated individuals from Northern Manhattan [93] or
families of speciﬁc background (i.e. the Dominican Republic or
Mexican-American) [39,79,94]. The type of analyses varied among
studies but none studied the effect of ancestry. Self-reported
ethnicity is not necessarily the same as the genotypic ethnicity
[80]. For instance, “Hispanic” designation from the USAWest Coast
is most likely to be a mixture of Asian, Native-American and Eu-
ropean ancestry, whereas “Hispanic” from the USA East Coast is
most likely to be a mixture of Native American, European and Af-
rican ancestry (Fig. 3). Therefore, studies that evaluate ethnicity/
Fig. 4. Association of allele variants for the SNP rs7768807 of the gene for interleukin
regulatory factor 4 involved in leukocyte function with changes in carotid intima-
medial thickness varied by the type of hormone treatment in women compliant to
treatment with either placebo (PL), transdermal 17b estradiol (E2) or oral conjugated
equine estrogen (oCEE) in the Kronos Early Estrogen Prevention Study (KEEPS). Minor
allele frequency for rs7768807 is 27%.
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geographical origins of ancestry using genetic data [95]. A valida-
tion study of susceptibility loci for coronary artery disease is a case
in point [96]. Although 4 loci associating with coronary artery
disease were common between the Han Chinese population and
European populations, 4 were unique to the Han Chinese (case
control study and the number of males or females was not included
in the report) [96]. Due to globalization, persons with multiracial
and multiethnic backgrounds are increasingly common place;
therefore, consideration of ancestral components of disease may
become more relevant to understanding inherited cardiovascular
risk. In the era of pharmacogenomics, biological factors will drive
response to treatment while self-report of ethnicity may be driven
by socio-political factors independent of biological factors.
4.2. Hormonal status
Nuclear receptors for the sex steroids affect gene transcription.
Therefore, if a gene carrying a particular SNP has a sex steroid re-
ceptor in the promoter region, the relative contribution of that SNP
to expression of the gene product will be affected by 1) hormonal
status; 2) genetic variants in receptors for sex steroids; 3) genetic
variants in enzymes required for metabolism (synthesis or degra-
dation) of sex steroids.
The ﬁrst studies suggesting that hormonal genetic variant
accelerate development of atherosclerosis was in a man with a
deletion of estrogen receptor alpha [97,98]. As estrogen modulates
endothelial nitric oxide synthase, this pathway is considered an
important mechanism by which estrogenic hormones slow pro-
gression of atherosclerosis. Variants in the gene for estrogen re-
ceptor alpha also associated with levels of high density lipoprotein
cholesterol and some inﬂammatory cytokines in women using es-
trogen for secondary prevention of cardiovascular disease [99,100].
However, neither variants of estrogen receptors alpha nor beta
signiﬁcantly associate with cardiovascular events in women of the
Women's Health Initiative where the use of estrogenic treatments
was used to evaluate primary prevention of cardiovascular disease
[101]. There were no consistent relationships between genetic
variants in either estrogen receptor alpha or beta and HDL levels in
perimenopausal women of various ethnicities [53]. Collectively,
these data suggest that perhaps variants in estrogen receptor genes
impact cardiovascular disease to a greater extent in men compared
to women.
The gene for the androgen receptor, which resides on the X
chromosome, contains a functional polymorphism consisting of
highly variable numbers of CAG repeats. Given the mosaic pattern
of X inactivation in women, variants in this gene will have a greater
impact in males than in females. There is signiﬁcant heterogeneity
in the CAG repeats among ethnic groups [102] which may explain,
in part, the inability to detect an association between these repeats
and heart disease in Caucasian men [103].
These CAG repeats in hypothalamic/pituitary regions of the
brain have a small effect on the feedback control for testosterone
production in men such that the higher number of repeats, the
higher the serum free testosterone levels [104]. These repeats are
associated with male infertility. In addition, they may impart some
cardiovascular risk as low numbers of repeats associated with
abdominal adiposity and higher sympathetic modulation of
vascular tone in boys than in girls. Data are conﬂicting regarding
the association of CAG repeats with serum levels of high density
lipoprotein cholesterol (HDL) and development of type 2 diabetes
in men [105]. In women, CAG repeats associate with polycystic
ovarian syndrome, characterized by male-pattern adiposity and
propensity for development of type 2 diabetes [106,107].
In addition to hormonal receptors, there are genetic variants inenzymes involved with synthesis, conversion and degradation of
the sex steroids. However, little attention has focused on these
variants with hormonal modulation of cardiovascular disease pro-
cesses in men or women. For example, SULT1A1, an ubiquitous
enzyme that is the predominant sulfotransferase present in the
liver, is highly polymorphic including copy number and multiple
single nucleotide polymorphisms that affect enzyme activity
[108,109]. Thus, a gene “dose” effect of SNP by copy number could
affect response to various hormonal therapies impacting vascular
function including endothelium-derived nitric oxide. In addition,
biological effects of SNPS on this enzyme seem to vary by ethnicity
as an SNP in the promoter region decreased SULTA1A1 activity in
African Americans but increased activity in Caucasians [110]. Vari-
ation in genes for other enzymes in the estrogen metabolic
pathway and their association with menopausal vasomotor symp-
toms also show differences among ethnic groups [111e113]. How-
ever, studies linking menopausal symptoms and genotypes to
cardiovascular disease are lacking.
Hormonal status affects phenotypic consequences of SNP
expression. For example, in unpublished data from our group
(Moyer, et al.), the signiﬁcance of an association of the G allele in
SNP of interleukin regulatory factor 4 with change in carotid
intima-medial thickness in women of the KEEPS trial varied
depending on the treatment assignment (Fig. 4).
These observations point to several important considerations in
evaluating genetic contributions to cardiovascular disease. First,
attention should be given to ethnicity veriﬁed by genetic data
rather than self-identiﬁcation. Second, since hormonal status varies
across the life span in both men and women, hormonal status, age
and sex should be considered when evaluating speciﬁc genetic
contributions to cardiovascular risk. Finally, studies to examine
genetic basis of hormonal inﬂuences on cardiovascular function
should continue given the on-going use of hormonal products by
women and increased use of exogenous testosterone by men.5. Statistical considerations for future studies
As genetic studies go forward, there are several important
considerations that need to be incorporated into analyses. For
example, population geneticists study the distribution and changes
of allele frequency in a given population due to natural selection,
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recombination, population subdivision and population structure.
Therefore, in genetic studies of admixed populations, it is relevant
to assess if the self-reported ancestry is the same as genotypic
ancestry. As discussed above, this can be accomplished by calcu-
lating the proportion of ancestry derived from each geographical
region using ancestry informative markers (see Fig. 3).
It is also important to consider the statistical analysis method in
genetic association studies because of possible confounding of the
number of X chromosomal variants by sex. Univariate linear or
logistic regression or standard chi-square tests are typically used
for the autosomes and these tests can still be applied for the
pseudoautosomal regions of the X and Y chromosomes. However,
different analysis methods are necessary when analyzing X chro-
mosome variants outside of this region. For the regions undergoing
X-inactivation, the statistical analysis should account for this
process.
However, some methods to account for X-inactivation have not
yet been adopted by the research community because they are not
readily available in statistical software packages. Those currently
available include PLINK for genome-wide analysis [114] and R/
Bioconductor package ‘snpMatrix’ (http://www.bioconductor.org)
[115] which both allow for statistical tests of X chromosome vari-
ants, and IMPUTE2 [116], which allows for genome-wide imputa-
tion of untyped/missing variants on the X chromosome.
Most methods to analyze X chromosome data have been
developed and evaluated univariately, rather than considering
multivariate models with multiple genetic factors. As complex trait
etiology likely involves a large number of genetic and environ-
mental components, this is a critical research area. Furthermore,
studies of the genetics of sex differences should not be limited to
variants on the sex chromosomes. Autosomal genetic effects can
also be modiﬁed by sex, and geneesex interactions effects may
underlie observed sex differences in disease traits. Interactions
between autosomal variants and sex may be surrogates for gen-
eegene interactions between variants on the autosomes and the X
or Y chromosomes, as well as gene by hormone interaction effects
[117]. In fact, many autosomal sequence variants that are associated
with gene expression (eQTLs) display sex differences, and such sex-
biased effects on expression are observed for important regulatory
genes [118]; thus, studies of geneesex interactions may be critical
tools to explore the genetics of sex differences. Recently many
statistical methods have been developed to explore gene-
eenvironment interactions [119,120]. Such methods could be
applied to study sex-speciﬁc genetic effects, and represent an
important opportunity for future research especially related to
cardiovascular disease.
6. Summary/conclusions
Cardiovascular diseases represent complex genetic traits with
phenotypes being inﬂuenced by genetic, hormonal, environmental,
and cultural variables. Although many studies have attempted to
gain insight into etiology of various cardiovascular diseases and
their risk factors through genetic analyses, most have ignored the
basic genetics contributed by the sex chromosomes and have failed
to conduct sex-stratiﬁed analyses, despite emerging tools to study
the genetics of sex differences for complex traits. Furthermore, the
confounding effects of ancestry and hormonal status across the life-
span also need to be considered. Given that sex differences in
incidence, prevalence, morbidity andmortality from cardiovascular
diseases are documented around theworld, sexmust be considered
in future investigations of genetic components of the disease if
preventive, diagnostic and treatment strategies are to be individ-
ualized to optimize outcomes.Conﬂicts of interest
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